Abstract Number: 474 • 2012 ACR/ARHP Annual Meeting
Dose Reduction in Rituximab Retreatment May Delay Achievement of Optimal Responses
Background/Purpose: The best long-term treatment strategy for rituximab has not been established. Retreatment at a fixed interval of 6 months maintains stable disease activity1 and…Abstract Number: 475 • 2012 ACR/ARHP Annual Meeting
Immunologic Responsiveness in Patients with Juvenile Idiopathic Arthritis On Methotrexate and Etanercept: 23 Valent Pneumococcal Vaccination
Background/Purpose: There is a paucity of data regarding response to vaccinations in patients with juvenile idiopathic arthritis (JIA) treated with methotrexate (MTX). It is also…Abstract Number: 476 • 2012 ACR/ARHP Annual Meeting
Effects of Vitamin D Repletion and Maintenance Therapy On Clinical Indicators of Disease Activity in Rheumatoid Arthritis
Background/Purpose: Low Vitamin D levels are prevalent in Rheumatoid Arthritis (RA). We have previously reported that low vitamin D levels are associated with higher…Abstract Number: 477 • 2012 ACR/ARHP Annual Meeting
Impact of Etanercept On Incident Cancer in Taiwanese Patients with Rheumatoid Arthritis
Background/Purpose: The recent Taiwanese report has indicated an elevated risk of malignancy in RA patients1. Etanercept, one of the tumor necrotic factor inhibitors (TNF-I) to…Abstract Number: 478 • 2012 ACR/ARHP Annual Meeting
Body Mass Index Negatively Influences the Response to Infliximab in Rheumatoid Arthritis
Background/Purpose: The excess of adipose tissue in obese individuals may have immunomodulating properties and pharmacokinetics consequences. Adipose tissue is potentially involved in the regulation of…Abstract Number: 479 • 2012 ACR/ARHP Annual Meeting
Active Immunization with TNF-Kinoid in Rheumatoid Arthritis Patients with Secondary Resistance to Tumor Necrosis Factor-Alpha Antagonists Is Safe and Immunogenic
Background/Purpose: Blocking TNF alpha (TNFα) with monoclonal antibodies (mAbs) has been successful in the treatment of rheumatoid arthritis. However secondary resistances are frequent and impose…Abstract Number: 480 • 2012 ACR/ARHP Annual Meeting
Etanercept Induces A Significant Decrease of Oxidative Stress and Osteoprotegerin Compared with Sdmard in Patients with Rheumatoid Arthritis
Background/Purpose: TNF-inhibitors are known to decrease cardiovascular events in rheumatoid arthritis (RA) as compared with synthetic disease modifying anti-rheumatic drugs (sDMARD). However, mechanisms involved remain…Abstract Number: 481 • 2012 ACR/ARHP Annual Meeting
Duration of Sustained Remission and Differences in Responce Between Medications, in Tumor Necrosis factor inhibitor Treated Rheumatoid Arthritis Patients
Background/Purpose: Remission is increasingly becoming a treatment goal in rheumatoid arthritis (RA) patients and DAS28 remission criteria are widely used, despite their limitations. The purpose…Abstract Number: 482 • 2012 ACR/ARHP Annual Meeting
B-Lymphocyte Count Is Not Associated with an Increased Risk of Infection in Patients Treated with Rituximab for Auto-Immune Diseases
Background/Purpose: B-Lymphocyte (B-Ly) depletion therapy with the monoclonal anti-CD20 antibody rituximab (RTX) is widely used in a variety of autoimmune (AI) diseases. The risk of…Abstract Number: 483 • 2012 ACR/ARHP Annual Meeting
An Evaluation of Literature On Discontinuation Rates of Biologics in Rheumatoid Arthritis
Background/Purpose: To assess reasons for biologic discontinuation or switching in the treatment of rheumatoid arthritis (RA). Methods: A text mining strategy was developed to identify, from the biomedical…Abstract Number: 484 • 2012 ACR/ARHP Annual Meeting
Comparison of Rheumatoid Arthritis-Related Health Care Resource Use and Comorbidities Among Patients with Rheumatoid Arthritis Treated with Adalimumab Vs. Etanercept
Background/Purpose: Adalimumab (ADA) and etanercept (ETN) are two commonly used tumor necrosis factor (TNF)-α antagonists for the treatment of rheumatoid arthritis (RA). The study is…Abstract Number: 485 • 2012 ACR/ARHP Annual Meeting
Immunogenicity of Infliximab Is Related to Reduction of Frequency of Infliximab Administration in Rheumatoid Arthritis and Spondyloarthritis Patients
Background/Purpose: To analyze the clinical and biological characteristics associated with presence of antibodies to Infliximab, in rheumatoid arthritis (RA) and spondyloarthritis patients (SpA). Methods: Sera…Abstract Number: 486 • 2012 ACR/ARHP Annual Meeting
Impact of Adalimumab Therapy On Laboratory Parameters of Interest in Patients with Early or Long-Standing Rheumatoid Arthritis
Background/Purpose: The systemic inflammation of rheumatoid arthritis (RA) can have detrimental effects on the hematopoietic and cardiovascular systems. Additionally, effective DMARD treatments for RA can…Abstract Number: 487 • 2012 ACR/ARHP Annual Meeting
Functional Disability in Early Rheumatoid Arthritis – Contributions of Disease Activity and Structural Damage, and the Impact of Different Treatment Strategies
Background/Purpose: Functional impairment among patients with rheumatoid arthritis (RA) can be conceptualized as consisting of a reversible component that relates to disease activity (ACT-HAQ) and…Abstract Number: 488 • 2012 ACR/ARHP Annual Meeting
Patient Preferences for Biologic Treatments in Rheumatoid Arthritis
Background/Purpose: Patients with rheumatoid arthritis (RA) and their physicians face a range of treatment choices. The treatments that patients receive should be driven partly by…